Analytical Data
-
基因名
NPFFR2
- Application
-
别名
/
-
种属
Human
-
表达系统
Yeast
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
A0PJM9
-
表达区间
1-420aa
-
分子量
50.7 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NPFFR2, or Neuropeptide FF receptor 2, is a G-protein-coupled receptor (GPCR) known for its role in several physiological processes, including pain modulation, stress response, and neuroinflammation. Research indicates that NPFFR2 may be involved in the regulation of nociceptive pathways, potentially offering insights into pain management strategies. The receptor binds neuropeptides such as neuropeptide FF and neuropeptide AF, which can influence the analgesic effects and may interact with other signaling pathways in the central nervous system. Given the prevalence of chronic pain conditions and the limitations of current analgesics, understanding NPFFR2 could lead to novel therapeutic targets for pain relief. Furthermore, studies have suggested its involvement in various neuropsychiatric disorders, making it a promising candidate for drug development. Recombinant protein studies of NPFFR2 aim to elucidate its structural characteristics, ligand-binding affinities, and downstream signaling mechanisms, providing a foundation for future pharmacological interventions. The exploration of this receptor represents a critical frontier in neurobiology, with the potential to revolutionize approaches to treating complex pain syndromes and related disorders.
